Medtronic Hired New Cardiac Ablation Executive

The Minnesota-based medical device maker added Felicia Kurz to lead its cardiac ablation solutions division.

Updated on Oct. 6, 2026 in Healthcare

Isometric editorial illustration of a surgical cardiac ablation catheter probe on a sterile surface, representing medical device innovation. — Medtronic has appointed Felicia Kurz as the new Vice President of Cardiac Ablation Solutions to drive growth and commercial strategy for its technology portfolio. AI Illustration. Upload story photo >

Live Poll

Do you trust that executive leadership changes at major medical companies improve healthcare outcomes?

Medtronic has appointed Felicia Kurz as the new Vice President of Cardiac Ablation Solutions. The move comes as the company focuses on scaling its operations within the electrophysiology sector.

Why it matters

By recruiting an executive with extensive commercial strategy experience, Medtronic intends to accelerate growth for its cardiac technology portfolio. The leadership change supports the firm's plans to continue reinvesting in its advanced ablation platforms.

Felicia Kurz brings 10 years of industry experience to her new role, including 3 years served as Senior Vice President of Advanced Therapies for North America at Siemens Healthineers.

The players

Medtronic

This Minnesota-based medical device company is a global leader in health technology and is currently expanding its electrophysiology business.

Felicia Kurz

She is the newly appointed Vice President of Cardiac Ablation Solutions who previously held a senior leadership role at Siemens Healthineers.

Rebecca Seidel

She is a leader at Medtronic who announced the company's newest executive hire through professional social media channels.

Siemens Healthineers

This global medical technology company focuses on imaging, diagnostics, and advanced therapies.

The details

Rebecca Seidel announced the new appointment via a LinkedIn post, highlighting the need for commercial strategy and global team leadership. Medtronic continues to build upon its Affera platform, which recently received an expanded indication for ventricular tachycardia and premature ventricular complexes.

The Affera system received an expanded indication in the European Union in September 2026.
Rebecca Seidel announced the hiring of Felicia Kurz on October 5, 2026.

Market Landscape

The hiring of a new executive is intended to drive the market adoption and global scaling of the Affera Sphere-9 pulsed-field ablation catheter. This strategic addition follows the recent expansion of the platform's regulatory indications, positioning Medtronic to compete more aggressively in the electrophysiology sector.

For patients and healthcare providers, this leadership change signifies an increased focus on the availability and technological evolution of cardiac ablation treatments. The move may result in faster adoption of newer, less invasive technologies for treating ventricular tachycardia and related conditions.

The takeaway

Medtronic is heavily prioritizing its electrophysiology business to maintain its competitive edge in cardiovascular health. New leadership often serves as a precursor to shifted commercial priorities and faster product deployment in the medical device market.